Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$198.26 USD
+5.36 (2.78%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $198.38 +0.12 (0.06%) 5:38 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Brokerage Reports
Charles River Laboratories International, Inc. [CRL]
Reports for Purchase
Showing records 341 - 360 ( 393 total )
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Research Summary
Provider: KEYBANC CAPITAL MARKETS
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Initiating Coverage on Charles River Laboratories with a Neutral Rating and $115 PT
Provider: Mitsubishi UFG Securities (USA)
Analyst: TWIZELL J
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Morning Call
Provider: KEYBANC CAPITAL MARKETS
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Healthcare IT, Biopharmaceutical Services and Laboratories: Post-1Q17 Model Book
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Research Summary
Provider: KEYBANC CAPITAL MARKETS
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Healthcare IT, Biopharmaceutical Services and Laboratories: Post-4Q16 Model Book
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D